I am neutral on Pfizer (PFE) as it has a strong competitive position within the pharmaceutical and biotechnology industry, strong growth momentum, and discounted valuation multiples relative to the company’s trading history. On the other hand, the average price target implies weak upside potential over the next year. Pfizer is a Fortune 500 company headquartered in New York, producing vaccines and medicines for cardiology, endocrinology, immunology, oncology, and neurology. The company was established in 1849 by Charles Pfizer and Charles F. Erhart, with plants producing fine chemicals.  The company has its operations in several countries, which enable it to benefit from economic surges even when some markets may crash.
https://www.tipranks.com/news/article/pfizer-stock-discounted-valuation-multiples?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
過去 株価チャート
から 4 2022 まで 5 2022 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 5 2021 まで 5 2022 Pfizerのチャートをもっと見るにはこちらをクリック